Resistance to treatment and the appearance of secondary tumors in head and neck squamous cell carcinomas (HNSCC) have been attributed to the presence of cells with stem-cell-like properties in the basal layer of the epithelium at the site of the lesion. In this study, we tested the hypothesis that these putative cancer stem cells (CSC) in HNSCC could be specifically targeted and inhibited. We found that 9 of 10 head and neck tumor biopsies contained a subpopulation of cells that expressed CD133, an unusual surface-exposed membrane-spanning glycoprotein associated with CSC. A genetically modified cytolethal distending toxin (Cdt), from the periodontal pathogen Aggregatibacter actinomycetemcomitans, was conjugated to an anti-human CD133 monoclonal antibody (MAb). The Cdt-MAb complex preferentially inhibited the proliferation of CD133 + cells in cultures of established cell lines derived from HNSCC. Inhibition of the CD133 + cells was rate-and dosedependent. Saturation kinetics indicated that the response to the Cdt-MAb complex was specific. Healthy primary gingival epithelial cells that are native targets of the wild-type Cdt were not affected. Analysis of these data provides a foundation for the future development of new therapies to target CSC in the early treatment of HNSCC. Abbreviations: Cdt, cytolethal distending toxin; CSC, cancer stem cells; HNSCC, head and neck squamous cell carcinoma; MAb, monoclonal antibody.
H
ead and neck squamous cell cancer afflicts over half a million people worldwide. Efforts to reduce the morbidity and mortality (40% survival at 5 yrs) of the disease are compromised by the development of resistance to chemotherapeutic agents and the occurrence of secondary tumors.
Resistance to treatment and the appearance of secondary tumors have been attributed to the presence of cancer cells that have stem-cell-like properties (Fiala, 1968) . Cell lines derived from primary head and neck squamous cell carcinomas (HNSCC) contain a subpopulation of cells with clonogenic characteristics (Mackenzie, 2004) and can retain this subpopulation years after isolation and in vitro passage (Locke et al., 2005; Harper et al., 2007) . Stem cells present in the basal layer of the epithelium mutate to create a clonal unit that becomes an expanding field. Clonal selection, in combination with other factors, contributes to the development of a carcinoma. Secondary tumors that arise can be clonally related and derived from expansion of the original clone (Braakhuis et al., 2004) . Therapies that target cells with acquired stem-celllike properties early in tumor development may have utility in the treatment of early-stage head and neck cancer (Jones et al., 2004; Choi and Myers, 2008) .
The objective of this study was to examine, in vitro, a novel strategy designed specifically to target and inhibit cells with acquired stem-cell-like properties in HNSCC using a genotoxin produced by the periodontal pathogen Aggregatibacter actinomycetemcomitans (Mayer et al., 1999) . This cytolethal distending toxin (Cdt) is composed of CdtA (18-25 kDa) and CdtC (21 kDa) subunits, which bind to a receptor on the cell surface, and CdtB (31 kDa), which is related to a superfamily of Mg 2+ -dependent phosphohydrolases (Hofmann et al., 2000) . CdtB appears to act as a neutral, cation-dependent nuclease that damages host DNA (Elwell and Dreyfus, 2000; Lara-Tejero and Galán, 2000) . DNA damage leads to growth arrest at the G 2 /M interphase of the cell cycle, due to inhibition of dephosphorylation of the checkpoint protein kinase Cdc2 (Alby et al., 2001) . Cells of epithelial origin appear to be natural targets of the A. actinomycetemcomitans Cdt (Kanno et al., 2005) .
In this report, we provide evidence that cell lines and tissue derived from HNSCC contain a subpopulation of cells that express a unique antigen, known as CD133. We show that an anti-human CD133 MAb conjugated to a genetically modified Cdt specifically targets and inhibits the proliferation of this subpopulation of cells. Analysis of these data provides an important foundation for the future development of approaches designed to attack cells with acquired stem-cell-like properties for the early treatment of HNSCC. 
MATERIALS & METHODS

HnSCC Cell Lines and Tumor Biopsies
CAL-27 and the mouse B-cell hybridoma cell line HB-12346™ (AC133.1) were cultured in DMEM and FaDu, RPMI 2650, and Caco-2 in EMEM media. These cell lines were obtained from the ATCC (Rockville, MD, USA). JHU006 and JHU012 were cultured in RPMI 1640 medium (Khan et al., 2010) . Media were supplemented with 10-20% fetal calf serum (FCS). Primary HGEC were isolated (Oda and Watson, 1990) 
Immunofluorescence Staining
Immunofluorescence microscopy was performed as described previously (Kanno et al., 2005 
Real-time PCR
Total RNA was isolated from cells with the Trizol reagent, and cDNA was prepared from 2 µg of RNA with oligo(dT) and the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). Reactions were preformed in an ABI 7300 RealTime PCR System (Applied Biosystems, Foster City, CA, USA) with primers 5′-GAGAAAGTGGCATCGTGCAA-3′ (forward) and 5′-TGCCAAACCAAAACAAATTCAA-3′ (reverse). TATAbinding protein (TBP) mRNA, amplified with 5′-GGAGCTGT GATGTGAAGTTTCCTA-3′ (forward) and 5′-CCAGGAAA TAACTCTGGCTCATAAC-3′ (reverse) primers, served as a normalizing control. A negative PCR control without template cDNA was included.
Western Blotting
CD133 was detected in cell lysates with an Enhanced Chemiluminescence Western Blotting Detection Kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) after binding of mouse anti-human CD133/1 (AC133) MAb (Miltenyi Biotec) and horseradish peroxidase (HPR)-conjugated anti-mouse IgG (Novagen, San Diego, CA, USA) (Mao and DiRienzo, 2002) . A lysate of Caco-2 cells was used as a positive control (Corbeil et al., 2000) . Actin was labeled with rabbit anti-human actin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and HRPconjugated anti-rabbit IgG (GE Healthcare, Piscataway NJ, USA).
Site-specific Mutagenesis of CdtA C178, in CdtA, was replaced with alanine by site-directed mutagenesis with the primers 5′-AAAAGTGTGTCACAAGGAC GTGCAGTCACTTA TAATCCTG TAAGTCC-3′ (forward) and 5′-GGACTTACAGGATTATAAGTGACTGCACGTCCTTGT GACACACTTTT-3′ (reverse) (alanine codons underlined). Mutated DNA strands were made with PfuUltra DNA polymerase in PCR (Stratagene, La Jolla, CA, USA). Template DNA was obtained from pMUTc149cdtA that contained the amino acid substitution C149A in CdtA (Cao et al., 2006) . Methylated parental DNA strands were digested with DpnI (New England Biolabs, Beverly, MA, USA) prior to transformation of Escherichia coli TOP10 competent cells (Invitrogen). The mutation was confirmed by DNA sequencing, and E. coli BL-21 competent cells (Novagen) were transformed for isolation of the mutated gene product, designated CdtA C149A, C178A
.
Protein Isolation and Toxin Reconstitution
Recombinant Cdt proteins were isolated by affinity chromatography as described previously (Cao et al., 2005) . Heterotrimers were reconstituted, in a refolding buffer, from wild-type subunits, CdtA C149A, C178A -His 6 and MAb-conjugated CdtA C149A, C178A -His 6 (Mao and DiRienzo, 2002) . Heterotrimer formation was confirmed by differential dialysis followed by Western blotting (Cao et al., 2005) .
CdtA Binding Assay
We used a cell enzyme-linked immunosorbent assay (CELISA) to examine binding kinetics of CdtA C149A, C178A -His 6 (Cao et al., 2005) . We seeded 96-well microtiter plates with 1.5 x 10 4 RPMI 2650 or FaDu cells/well in growth medium and incubated them for 48 hrs. The cells were fixed, and a 0-2 µg quantity of purified CdtA C149A, C178A -His 6 or CdtA-His 6 was added to each well. Bound protein was detected, after 1 hr, with anti-His•Tag MAb (Novagen).
Monoclonal Antibody Conjugation to CdtA
IgG1 was purified from AC133.1 mouse hybridoma culture medium with the Montage™ Antibody Purification PROSEP-A Kit (Millipore, Billerica, MA, USA). Antibody concentration was determined according to the Beer-Lambert Law [IgG (mg/ mL) = A 280 x 0.72], and a titer was obtained with a whole-cell lysate of Caco-2 cells. The IgG1 was conjugated to CdtA C149A, C178A -His 6 , with 4-succinimidyloxy carbonyl-α-methyl-α-(2-pyridyldithio)toluene (SMPT; Pierce, Rockford, IL, USA; 1 mg SMPT/10 mg of IgG) as described previously (Ghetie et al., 1991) . CdtA C149A, C178A -His 6 (0.5 mg) was mixed with SMPTMAb, and the preparation was incubated for 48 hrs at 4°C. Un conjugated excess SMTP-MAb was removed on a nickel-iminodiacetic acid column. Unconjugated CdtA C149A, C178A -His 6 was removed by dialysis, and the final protein concentration was determined with a Micro BCA Protein Assay Kit (Pierce).
Cell Cycle Analysis
Cell cycle arrest was determined by flow cytometry (Cao et al., 2005) . Cells were grown for 24 hrs (80-90% confluent) and incubated for 24 or 36 hrs with 2.5 or 10 µg/mL of one of the following (Yamada et al., 2006) modeled with UCSF Chimera (Pettersen et al., 2004) and Protein Data Bank (PDB) file 2F2F. Essential active-site residues H160 and H274 in CdtB are shown in cyan, and cysteine residues in CdtA are displayed in magenta. Insert shows a surface model of CdtA, rotated 90° counterclockwise relative to that in the ribbon structure, to show surface-exposed C149 and C197. Brackets mark two predicted disulfides, C136/C149 and C178/C197 (Cao et al., 2006) , and the two mutations, C149A and C178A. Mouse anti-human AC133.1 MAb was attached to C197 in CdtA BC-CD133MAb for 36 hrs, the percentage of cells having a 4n DNA content (diploid G2) were quantified by flow cytometry and plotted against the input concentration of toxin. Regression analysis showed that the dose response was linear (dashed line), with an R-squared value (square of the correlation coefficient) of 0.99, up to 16 µg/mL of protein/1 x 10 6 cells (at time of toxin addition). Saturation kinetics showed that the effect on cell cycle was specific and indicated that CD133 + cells comprised approximately 18% of the total cell culture. Kinetic experiments were performed twice. 
Cell Viability Assay
RESuLTS
Gene Expression and Cell-surface Display of CD133 in Oral Cancer Cells
Nine of 10 biopsies, from different patients, contained CD133 + cells (Fig.  1A) in the following distributions: > 75% (n = 2), 30-75% (n = 1), 10-30% (n = 5), and < 10% (n = 1). Among the 5 cell lines examined, CD133 + cells were detected by immunofluorescence in JHU006, JHU012, and RPMI 2650 cultures (Fig. 1B) .
CD133 was detected on the surface of RPMI 2650 cells by flow cytometry (Fig.  1C) (Fig. 1D) . CD133 expression by CAL-27 was orders of magnitude lower. The small amount of amplicon obtained from FaDu cDNA was not statistically significant. A CD133 mRNA was not detected in primary HGEC. These results matched exactly with the heterogeneous distribution of the CD133 protein as determined by Western blotting (Fig. 1E) .
Targeting the Cytolethal Distending Toxin (Cdt) to CD133 + HnSCC Cells
The recombinant A. actinomycetemcomitans Cdt inhibited the proliferation of all epithelioid cells examined to date. To target the Cdt specifically to CD133-expressing cells, we constructed a mutated CdtA subunit protein that no longer bound to the native toxin receptor and contained a single molecular surface exposed cysteine (C197) for conjugating the anti-human CD133 MAb ( Fig. 2A) . This mutant, CdtA C149A, C178A , lost the ability to bind to Cdt-sensitive RPMI 2650 and FaDu cells (Fig. 2B) . The reduction in cell binding was statistically significant and observed over input protein concentrations of ≥ 250 ng per well. CdtA C149A, C178A retained the ability to form a heterotrimer with wild-type CdtB and CdtC (Fig. 2B inset) . 6 cells) of RPMI 2650 and JHU012 were left untreated or treated with 10 or 2.5 µg/mL of CdtABC or CdtA C149A, C178A BC-CD133MAb for 36 or 24 hrs, respectively. Caco-2 (positive control), FaDu (negative control), and HGEC (normal oral keratinocytes) were treated with 10 µg/mL of protein for 36 hrs. Propidium-iodidestained nuclei were examined by flow cytometry. ModFit was used to generate the plots. The stained DNA profile is shown as the heavy black line. Experiments were performed a minimum of three times.
Selective Inhibition of CD133
+ Cells in Head and neck Squamous Cell Carcinoma Cell Lines BC-CD133MAb over a period of 24-72 hrs ( Fig. 2C ; blue bars). We observed a similar 33 to 81% decrease (white bars) in viability over the same time period of exposure to CdtABC. However, there was no specific decrease (orange bars) in the number of live cells after treatment with CdtA C149A, C178A BC. RPMI 2650 was cell-cycle-arrested in a dose-dependent fashion when treated with CdtA C149A, C178A BC-CD133 MAb (Fig. 2D) . The response was linear over the range 0 to 16 µg/mL of protein (R-squared = 0.99). Saturation kinetics was observed, and maximum cell cycle arrest (18% of the total cell population) was attained with 22 µg/mL of protein. This response was well below that of RPMI 2650 cells treated with the wild-type Cdt under the same conditions. Analysis of these data supported the results of the immunofluorescence experiments and cell sorting (data not shown), which indicated that the CD133 + cells comprised a subset (approximately 16-20%) of the total cell population. On average, 26.4 ± 0.6% (P = 0.002) of the total RPMI 2650 cell population had a 4n DNA content following a 36-hour exposure to a TD 50 of CdtA C149A, C178A BC-CD133MAb. In comparison, 54.0 ± 1.6% (P = 0.001) and 8.5 ± 0.7% of the total cells had a 4n DNA content after exposure to the same concentration of CdtABC and no toxin, respectively.
Following treatment with CdtA C149A, C178A
BC-CD133MAb for 36 hrs, RPMI 2650 and JHU012 contained a subpopulation of cells with a 4n DNA content indicative of cell-cycle arrest at G 2 /M (Fig.  3) . On average, 15, 84, and 19% of the total RPMI 2650, JH012, and Caco-2 cell populations (3.5 x 10 6 cells), respectively, had a 4n DNA content after treatment with 10 µg/mL of toxin (Table) . Cultures treated with either the CD133 MAb (AC133.1) alone or with toxin reconstituted with the unconjugated CdtA mutant (CdtA C149A, C178A BC) did not exhibit cell-cycle arrest. Both primary and immortalized HGEC were not affected by CdtA C149A, C178A BCCD133MAb, even though > 90% of these cells arrested at G 2 /M when treated with the wild-type Cdt. NT, not tested. *The increase in the diploid G2 population was statistically significant (P < 0.005) when compared with that for untreated cells.
DISCuSSIOn
There is evidence that HNSCC may be maintained by a subpopulation of cells with acquired stem-cell-like properties (Hamburger and Salmon, 1977) . These cells form "cancer spheroids" in culture and tumors when transplanted into mice (Harper et al., 2007; Prince et al., 2007) . CD133, a 120-kDa cell-surface glycoprotein (Shmelkov et al., 2005) , appears to be uniquely expressed by these cells (Harper et al., 2007; Okamoto et al., 2009) . Less than 0.2% of cells in cultures of the cell lines CA1, CaLH2, Cal-27, and FaDu exhibited high expression of CD133 (Harper et al., 2007; Cameron et al., 2010) . Zhang et al. (2009) found that 3 HNSCC cell lines and 10 biopsy samples contained up to 2% and 3% CD133 + cells, respectively. Approximately 60% of the cells with stem-cell-like properties in the cell lines SAS and OECM1 bound a CD133 antibody (Chiou et al., 2008) . Two of 5 HNSCC cell lines (RPMI 2650 and JHU012) cultured in our study had relatively high numbers of CD133 + cells, and 2 cell lines (CAL-27 and FaDu) failed to express the CD133 gene at levels sufficient for detection of the glycoprotein on the cell surface. This differential expression may have been a consequence of cell passage in vitro. Our analysis of 10 HNSCC biopsies suggests that CD133 + cells may be more prevalent, but in relatively low numbers, in vivo, where conditions for tumor growth and metastasis are optimal. Cells with acquired stem-cell-like properties isolated from HNSCC, based on the expression of CD133, were resistant to standard chemotherapy in vitro and in vivo (Zhang et al., 2009) . These cells use ATP-binding cassette membrane transporters (Goodell et al., 1996) or high expression of aldehyde dehydrogenase (Storms et al., 1999) to rapidly export or degrade xenobiotics. Targeting the subpopulation of cells with acquired stem-cell-like properties and development of treatment procedures to overcome their potential drug resistance seems vital for both tumor growth inhibition and prevention of tumor recurrence (Tu et al., 2009) .
Our study appears to be the first proof-of-concept to demonstrate the selective inhibition of proliferation of cells with acquired stem-cell-like properties (CD133 + ) in heterogeneous HNSCC cell populations. The A. actinomycetemcomitans Cdt was chosen as the inhibitory component due to the sensitivity of epithelioid-like cells to the wild-type Cdt. Various human epithelial and keratinocyte cell lines are cell-cycle-arrested at G 2 /M when exposed to the Cdt (reviewed in Whitehouse et al., 1998) . Likewise, we found that GMSM-K, an immortalized orolabial cell line, is very sensitive to the toxin (Kanno et al., 2005) . To the best of our knowledge, the susceptibility of primary human epithelial cells to the Cdt had not been previously examined. Here, we report that proliferation of HGEC is inhibited by the native Cdt, and that these cells do not express the CD133 gene. Based on these findings, we mutated the primary receptor binding subunit (CdtA) of the toxin to eliminate intoxication of normal cells. Sonoporation has been used to deliver a plasmid containing the A. actinomycetemcomitans cdtB gene into Ca9-22, a human gingival squamous cell carcinoma cell line (Iwanaga et al., 2007) . Transfected cells underwent apoptosis when treated in vitro and in mice. However, specific cell delivery mechanisms have not been tested. We conjugated an anti-human CD133 MAb to Cdt, containing the mutated CdtA subunit, to specifically deliver the toxin to CD133-expressing cells. The CdtA C149A, C178A BC-CD133MAb inhibited proliferation only in cells that displayed detectable levels of CD133 on the surface. The relative disparities among the HNSCC cell lines in susceptibility to CdtA C149A, C178A
BC-CD133MAb could be attributed to variable levels of expression of the CD133 gene.
Molecular targeted therapy in which the products of selectively expressed genes that contribute to the neoplastic phenotype are exploited as targets of antibodies, small molecules, or genetic constructs is a promising therapeutic strategy (Choi and Myers, 2008) . Targeted therapy should have a higher therapeutic index and, therefore, be less toxic than cytotoxic drugs. Unfortunately, recombinant immunotoxins and immunoreagents have had a poor clinical track record, primarily due to problems with immunogenicity, selectivity, penetration into solid tumors (Schrama et al., 2006; Pastan et al., 2007) , and, possibly, failure to target tumorforming cells. Subsequent studies are required to evaluate targeted approaches for the inhibition of proliferation of CD133 + cells that could lead to impaired development of primary and secondary tumors in vivo. The toxin-monoclonal antibody complex may have utility, in a clinical setting, as a topical or locally delivered reagent for treating dysplastic lesions and very-earlystage masses that have the potential to develop into mature tumors.
